Business Context and Reporting Period
This Form 8-K Current Report was filed by Capricor Therapeutics, Inc. on April 28, 2021. The filing discloses the entry into a Material Definitive Agreement, specifically an Exclusive License Agreement between Capricor, Inc. (a wholly-owned subsidiary) and Johns Hopkins University (JHU). The agreement pertains to intellectual property rights related to exosome-mRNA vaccines and therapeutics.
Key Financial Metrics
This filing is a current report regarding a specific corporate event and does not contain comprehensive financial statements, revenue, profit, cash flow, or margin data for the reporting period. The only specific financial figures disclosed relate to the terms of the new license agreement:
- Upfront License Fee: $10,000 paid to JHU.
- Reimbursements: Capricor agreed to reimburse JHU for certain fees and costs related to patent prosecution.
- Milestone Payments: Fees are due upon meeting certain development milestones (specific amounts not disclosed).
- Royalties: Low single-digit royalties on sales of royalty-bearing products.
- Sublicensing: Double-digit percentage of non-royalty consideration from sublicenses.
- Minimum Annual Royalty: Obligatory starting in the third year of the agreement (amount not disclosed).
Material Changes
The primary material change is the acquisition of an exclusive, worldwide, royalty-bearing license from JHU. This grants Capricor the right to sublicense, conduct research, and develop and commercialize products using JHU's patent rights and know-how in the field of exosome-mRNA vaccines and therapeutics. The agreement term continues until the expiration of the last patent in each country or for 20 years if no patents issue.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The company announced this agreement via a press release on April 29, 2021, signaling a strategic expansion into exosome-mRNA therapeutics.
Risks and Contingencies:
- Termination by Capricor: Capricor may terminate the agreement upon 90 days' written notice at its discretion, or with 60 days' notice for specific patents or products.
- Termination for Cause: Either party may terminate if the other fails to perform obligations and fails to cure the breach within 60 days.
- Material Breach Triggers: Capricor faces termination risks for payment delinquency, failure to achieve milestones, failure to diligently develop products, non-compliance with record-keeping/audit obligations, voluntary bankruptcy/insolvency, or failure to meet insurance obligations.
- Competitive Harm: Certain terms were omitted from the filing to prevent competitive harm.
Investor Verification Checklist
- Verify the specific amounts for development milestone payments and the minimum annual royalty, as these were not disclosed in the 8-K.
- Review the full text of the License Agreement when filed as an exhibit to the Form 10-Q for the quarter ending June 30, 2021, to understand omitted terms.
- Assess the company's current cash position to determine the impact of the upfront fee, reimbursement obligations, and future milestone payments.
- Monitor the company's progress on the specified development milestones to avoid potential termination for failure to diligently develop products.